Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corvus Pharma Com
(NQ:
CRVS
)
8.940
+0.700 (+8.50%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corvus Pharma Com
< Previous
1
2
3
4
5
Next >
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
September 18, 2024
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
September 16, 2024
Via
Benzinga
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
August 07, 2024
Via
Benzinga
Earnings Outlook For Corvus Pharma
March 18, 2024
Via
Benzinga
Preview: Corvus Pharma's Earnings
November 06, 2023
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
An Overview of Corvus Pharma's Earnings
November 11, 2024
Via
Benzinga
Stellantis, MicroStrategy, Bit Digital And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 30, 2024
Via
Benzinga
Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
September 30, 2024
Via
Benzinga
The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
May 31, 2024
One of the best ways to spot opportunity in penny stocks to buy is by following insiders. Here are three to consider.
Via
InvestorPlace
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024
May 06, 2024
CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 09, 2024
Via
Benzinga
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
March 19, 2024
CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Earnings Scheduled For March 19, 2024
March 19, 2024
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 08, 2024
Via
Benzinga
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
January 23, 2024
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
December 09, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
November 02, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
November 01, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
October 31, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 06, 2023
Via
Benzinga
Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 07, 2023
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 100% to $1.7909 after the company's subsidiary Champion Safe has been bombarded with calls from safe dealers and customers looking for...
Via
Benzinga
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
September 06, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
August 18, 2023
Oppenheimer has initiated coverage on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) with an Outperform rating and a
Via
Benzinga
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.